SCHEMBL4673335

SCHEMBL4673335

O=C(O)C(O)=CC(=O)c1ccc(Cc2ccncc2)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 4/20 0.38
RAB9A P51151 4/20 0.36
ALDH1A1 P00352 4/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
USP2 O75604 2/20 0.34
HPGD P15428 2/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NPC1 O15118 3/20 0.34
NAMPT P43490 1/20 0.34
LMNA P02545 3/20 0.33
TP53 P04637 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ABL1 P00519 1/20 0.33
MAPT P10636 1/20 0.33
NFKB1 P19838 1/20 0.33
MAPK1 P28482 1/20 0.33
NFKB2 Q00653 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673330 1.00 TBXAS1 (0.38) TBXAS1RAB9AALDH1A1MEN1KMT2A
SCHEMBL4673397 0.87 ALOX5 (0.40) TBXAS1RAB9AALDH1A1MEN1KMT2A
SCHEMBL4673394 0.87 ALOX5 (0.40) TBXAS1RAB9AALDH1A1MEN1KMT2A
SCHEMBL4673762 0.83 ITGB1 (0.35) TBXAS1RAB9AALDH1A1MEN1KMT2A
SCHEMBL4676027 0.83 MAPT (0.39) TBXAS1RAB9AALDH1A1MEN1KMT2A
SCHEMBL4678283 0.83 ALOX5 (0.40) RAB9AALDH1A1MEN1KMT2AHPGD
SCHEMBL4673757 0.83 ITGB1 (0.35) TBXAS1RAB9AALDH1A1MEN1KMT2A
SCHEMBL4676029 0.83 MAPT (0.39) TBXAS1RAB9AALDH1A1MEN1KMT2A
SCHEMBL4678282 0.83 ALOX5 (0.40) RAB9AALDH1A1MEN1KMT2AHPGD
SCHEMBL4674260 0.81 KMT2A (0.46) TBXAS1ALDH1A1KMT2AHPGDHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 TBXAS1 3205/4885RAB9A 2021/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.